“It will change the rules of the game” … watch out for a vaccine that protects against corona in one dose

Operation Warp Speed’s senior advisor, which aims to accelerate production of emerging coronavirus vaccines, Mansaf Salawi, said the vaccine Johnson & Johnson worked on development could see the light of day in February if approved on the scheduled date.

The Johnson & Johnson vaccine differs from the “Pfizer” and “Moderna” vaccines in several respects, notably the fact that it consists of a single dose, whereas the vaccines available so far must receive two doses, with a interval of up to two weeks.

According to Slawi, the Johnson & Johnson vaccine could be a “game changer” in the face of the pandemic.

“I think it could be a complete game changer. We hope that this single-dose vaccine will be equivalent to the effectiveness of Moderna and Pfizer (the vaccines),” Al-Slaoui said in a video interview.

“We are increasingly confident that the efficacy review (of the Johnson & Johnson vaccine) will take place during the month of January,” he added.

Al-Salawi suggested that the company would request an emergency use of its vaccine in January and that it would be obtained no later than the first half of next February.

The Johnson & Johnson vaccine is expected to achieve faster access to the peak preventive phase in a period not exceeding weeks, as it does not need another dose weeks after receiving the first, like other vaccines.

Johnson & Johnson recently revealed that it is ready to begin the final stages of trials of its emerging coronavirus vaccine, and said it expects progress data related to the trials to appear by the end of next January.

Johnson & Johnson recently recruited 45,000 volunteers to participate in clinical trials of its vaccine.

According to the company’s statement, the high rate of Corona infection in the countries where its experiments are conducted impeded the ability to attract a larger number of volunteers.

The United States agreed with Johnson & Johnson to purchase 100 million doses of its vaccine, and the contract included an option to purchase an additional 200 million doses.